文献リスト

1) Foster MC, Hwang SJ, Larson MG, et al. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis. 2008; 52: 39-48

2) Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007; 30: 937-43

3) Navaneethan SD, Yehnert H, Moustarah F, et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4: 1565-74

4) Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008; 118: 1645-56

5) Dogra G, Irish A, Chan D, et al. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis. 2006; 48: 926-34

6) Xing G, Shimosawa T, Ogihara T, et al. Angiotensin II-induced insulin resistance is enhanced in adrenomedullin-deficient mice. Endocrinology. 2004; 145: 3647-51

7) Kurata A, Nishizawa H, Kihara S, et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006; 70: 1717-24

8) DeVinuesa SG, Goicoechea M, Kanter J, et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol. 2006: S206-12

9) Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant. 2009; 24: 1876-83

10) Xue M, Qian Q, Adaikalakoteswari A, et al. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes. 2008; 57: 2809-17

11) Jiang T, Huang Z, Lin Y, et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes. 2010; 59: 850-60

12) Zheng S, Carlcon EC, Yang L, et al. Podocyte-specific overexpression of the antioxidant metallothionein refuces diabetic nephropathy. J Am Soc Nephrol. 2008; 19: 2077-85

13) Coughlan MT, Thorburn DR, Penfold SA, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol. 2009; 20: 742-52

14) Tan AL, Sourris KC, Harcourt BE, et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2010; 298: F763-70

15) Reiniger N, Lau K, McCalla D, et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes. 2010; 59: 2043-54

16) Haag-Weber M, Krämer R, Haake R, et al. Low-GDP fluid (Gambrosol trio) attenuatesline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant. 2010; 25: 2288-96

17) dʼUscio LV, Smith LA, Katusic ZS. Erythropoietin increases expression and function of vascular copper- and zinc-containing superoxide dismutase. Hypertension. 2010; 55: 998-1004

18) Pawlak K, Pawlak D, Mysliwiec M. Erythropoietin therapy decreased tissue factor, its pathway inhibitor, and oxidative stress in peritoneal dialysis patients with diabetes. Nephron Clin Pract. 2007; 107: c20-5

19) Rancourt ME, Rodrigue ME, Agharazii M, et al. Role of oxidative stress in erythropoietin-induced hypertension in uremic rats. Am J Hypertens. 2010; 23: 314-20

20) Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153: 23-33

21) Onozato ML, Tojo A, Kobayashi N, et al. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant. 2007; 22: 1314-22

22) Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004; 351: 1941-51

23) Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007; 369: 1431-9

24) Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008; 51: 393-8

25) Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009; 151: 1-10

26) Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003; 108: 1831-8

27) White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003; 41: 1021-6

28) Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4: 542-51

29) Ando K, Ohtsu H, Arakawa Y, et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res. 2010; 33: 616-21

30) Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-17

31) Pitt B, Zannad F, Remme WJ, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21

32) Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009; 54: 505-12

33) Matsumoto Y, Kageyama S, Yakushigawa T, et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology. 2009; 114: 32-8

34) Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008; 14: 1370-6

35) Fujita T, Ando K, Nishimura H. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007; 72: 1543-9

36) Ishimitsu T, Kameda T, Akashiba A, et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res. 2007; 30: 621-6

37) Nakamura T, Sato E, Fujiwara N, et al. Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosiskers in early-stage chronic kidney disease. Am J Med Sci. 2010; 339: 157-63

38) Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007; 333: 321-6

39) Knight SF, Yuan J, Roy S, et al. Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol Renal Physiol. 2010; 298: F86-94

40) Briones AM, Rodríguez-Criado N, Hernanz R, et al. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension. 2009; 54: 142-9

41) Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007; 22: 118-27

42) Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008; 51: 1448-54

43) Shepherd J, Kastelein JJ, Bittner V, et al. Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007; 2: 1131-9

44) Atthobari J, Brantsma AH, Gansevoort RT, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant. 2006; 21: 3106-14

45) Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010; 55: 1266-73

46) Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008; 336: 645-51

47) Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-48

48) Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-407

49) Dobrian AD, Schriver SD, Khraibi AA, et al. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity, Hypertension. 2004; 43: 48-56

50) Toblli JE, Ferrini MG, Cao G, et al. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant. 2009; 24: 2384-91

51) Yang HC, Deleuze S, Zuo Y, et al. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol. 2009; 20: 2380-8

52) Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279-89

53) Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006; 24: 2047-55

54) Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008; 19: 182-7

55) Owada S, Maeba T, Sugano Y, et al. Spherical carbon adsorbent (AST-120) protects deterioration of renal function in chronic kidney disease rats through inhibition of reactive oxygen species production from mitochondria and reduction of serum lipid peroxidation. Nephron Exp Nephrol. 2010; 115: e101-11

56) Fujii H, Nishijima F, Goto S, et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009; 24: 2089-95

57) Akizawa T, Asano Y, Morita S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009; 54: 459-67

58) Barreto FC, Barreto DV, Liabeuf S. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009; 4: 1551-8

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp